Claims
- 1. A compound having the formula:
- 2. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 3. A method of treating a patient comprising administering to said patient a therapeutically effective amount of one or more of compounds, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 4. The method of claim 3 wherein said patient is suffering from a disease or disorder characterized by either or both of (1) abnormal calcium homeostasis and, (2) an abnormal amount of an intracellular or extracellular messenger whose production can be affected by calcium receptor activity.
- 5. A method for modulating the PTH level in a patient comprising administering to said patient an effective amount of a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 6. The method of claim 5 wherein said effective amount of said compound reduces said PTH level in a patient.
- 7. The method of claim 6 wherein said patient has an abnormally high PTH level and effective amount of said compound reduces said PTH level in said patient to a degree sufficient to cause a decrease in plasma Ca2+.
- 8. The method of claim 7, wherein administering said compound to said patient results in a PTH level in said patient equal to a level present in a normal individual.
- 9. A method for modulating parathyroid hormone secretion in a patient comprising administering to said patient an effective amount of a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 10. The method of claim 9 wherein said effective amount of said compound reduces said parathyroid hormone secretion in said patient.
- 11. The method of claim 10 wherein said patient has an abnormally high parathyroid secretion and said therapeutically effective amount of said compound reduces said parathyroid hormone secretion in said patient to a degree sufficient to cause a decrease on plasma Ca2+.
- 12. A method for modulating one or more Ca2+ receptors activities in a cell comprising administration to said cell one or more compounds, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 13. The method of claim 12 wherein said cell is a parathyroid cell, a juxtaglomerular kidney cell, a proximal tubule kidney cell, a parafollicular thyroid cell, a bone osteoclast, a keratinocyte or a placental trophoblast.
- 14. A method for treating or preventing a disorder selected from the group consisting of hyperparathyroidism, renal osteodystrophy, hypercalcemia malignancy, osteoporosis, Paget's disease and hypertension comprising administering to a patient suffering from said disorder a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula: wherein:
- 15. The method of claim 14 wherein said hyperparathyroidism is primary hyperparathyroidism.
- 16. The method of claim 15 wherein said hyperparathyroidism is secondary hyperparathyroidism.
- 17. A pharmaceutical composition for treatment of primary and secondary hyperparathyroidism comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 18. A pharmaceutical composition for treatment of renalosteodystrophy comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 19. A pharmaceutical composition for treatment of hypercalcemia comprising a compound, or, a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 20. A pharmaceutical composition for treatment of hypercalcemia malignancy comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 21. A pharmaceutical composition for treatment of osteoporosis comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula: wherein:
- 22. A compound selected from the group consisting of:
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of a co-pending U.S. application Ser. No. 10/053,133, filed on Jan. 17, 2002, which claims priority from U.S. application Ser. No. 09/214,552, filed Jan. 6, 1999, which claims priority to an International Application No. PCT/JP97/02358 filed on Jul. 8, 1997, which claims priority to Japanese Application Nos. 9/107778, filed Apr. 24, 1997; 8/350393, filed Dec. 27, 1996 and 8/178315, filed Jul. 8, 1996, all which are incorporated by reference herein.
Continuations (1)
|
Number |
Date |
Country |
Parent |
10053133 |
Jan 2002 |
US |
Child |
10243322 |
Nov 2002 |
US |